I. Pringle

发表

The use of CpG-free plasmids to mediate persistent gene expression following repeated aerosol delivery of pDNA/PEI complexes.

S. Abdullah, L. Davies, S. Hyde, 2012, Biomaterials.

Electroporation‐mediated interleukin‐10 overexpression in skeletal muscle reduces acute rejection in rat cardiac allografts

M. Genoni, S. Hyde, I. Pringle, 2006, The journal of gene medicine.

Identification and Functional Characterization of Cytoplasmic Determinants of Plasmid DNA Nuclear Import*

D. Geddes, M. Ward, M. Dunn, 2009, The Journal of Biological Chemistry.

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins

L. Davies, S. Hyde, I. Pringle, 2018, Gene Therapy.

The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways.

R. Scheule, Seng H. Cheng, P. Sinn, 2010, Biomaterials.

Preparation for a fi rst-inman lentivirus trial in patients with cystic fi brosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016 .

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016, Thorax.

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung

D. Porteous, D. Shaw, R. Scheule, 2011, Gene Therapy.

S127 Gene therapy for alpha-1-antitrypsin deficiency using a pseudotyped lentivirus vector

M. Hasegawa, I. Pringle, D. Gill, 2015 .

CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression

David N Sheppard, Uta Griesenbach, David J Porteous, 2008, Nature Biotechnology.

Transgene sequences free of CG dinucleotides lead to high level, long-term expression in the lung independent of plasmid backbone design.

L. Davies, S. Hyde, R. Bazzani, 2016, Biomaterials.

Preparation for a ﬁ rst-in-man lentivirus trial in patients with cystic ﬁ brosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016 .

Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy

A. Inness, J. Davies, M. Hasegawa, 2014 .

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung

D. Porteous, R. Scheule, J. Davies, 2013, Gene Therapy.

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.

D. Porteous, D. Shaw, R. Scheule, 2013, Biomaterials.

An immunocytochemical assay to detect human CFTR expression following gene transfer.

A. Nairn, D. Porteous, R. Gray, 2009, Molecular and cellular probes.

Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter

C. Higgins, S. Hyde, I. Pringle, 2001, Gene Therapy.

The formation of molecular clouds in spiral galaxies

I. Bonnell, I. Pringle, C. Dobbs, 2006, astro-ph/0602103.

Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis

R. Mayer, Paul A. Wilson, V. Jadhav, 2013, Molecular therapy. Nucleic acids.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

Steve Cunningham, Joseph Jacob, Sarah Sheard, 2015 .

Rapid identification of novel functional promoters for gene therapy

R. Scheule, Seng H. Cheng, L. Davies, 2012, Journal of Molecular Medicine.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

A. Doherty, T. Maher, A. Rodriguez-Martinez, 2016, Thorax.

Detection of plasmid DNA vectors following gene transfer to the murine airways

S. Hyde, I. Pringle, D. Gill, 2005, Gene Therapy.

Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA

M. Gottesman, D. Esposito, M. Hall, 2015, PloS one.

CpG-free plasmid expression cassettes for cystic fibrosis gene therapy.

L. Davies, S. Hyde, G. Nunez-Alonso, 2012, Biomaterials.

The development of gene therapy for diseases of the lung

L. Davies, S. Hyde, I. Pringle, 2004, Cellular and Molecular Life Sciences CMLS.

Rapid identification of novel functional promoters for gene therapy

R. Scheule, Seng H. Cheng, L. Davies, 2012, Journal of Molecular Medicine.

Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects

I. Pringle, D. Gill, S. Hyde, 2009, Expert opinion on biological therapy.

Progress and Prospects: The design and production of plasmid vectors

S. Hyde, I. Pringle, D. Gill, 2009, Gene Therapy.

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator ( CFTR) gene therapy in patients with cystic fibrosis

A. Nicholson, D. Hansell, A. Maclean, 2016 .

Limitations of the murine nose in the development of nonviral airway gene transfer.

D. Porteous, Charanjit Singh, R. Scheule, 2010, American journal of respiratory cell and molecular biology.

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins

L. Davies, S. Hyde, I. Pringle, 2018, Gene Therapy.

534. Preparation for a First-in-Man Lentivirus Trial in Cystic Fibrosis Patients

J. Davies, M. Hasegawa, L. Davies, 2016 .

Electroporation enhances reporter gene expression following delivery of naked plasmid DNA to the lung

D. Porteous, Seng H. Cheng, L. Davies, 2007, The journal of gene medicine.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

A. Nicholson, D. Hansell, A. Maclean, 2015, The Lancet. Respiratory medicine.

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.

R. Scheule, J. Davies, S. Hyde, 2013, Biomaterials.

Safety and adverse events

A. Nicholson, D. Hansell, A. Maclean, 2016 .